Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has been given a consensus rating of “Buy” by the thirteen research ...

The most recent trading session ended with Viking Therapeutics, Inc. (VKTX) standing at $29.28, reflecting a +1.14% shift from the previouse trading day's closing. The stock's change was less than ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study.

Viking Therapeutics, Inc. has a 12 month low of $24.41 and a 12 month high of $89.10. The firm’s 50-day moving average is $30.84 and its 200 day moving average is $47.33.

Excellent clinical trial data caused Viking Therapeutics stock to shoot higher in 2024. Eli Lilly markets a diabetes and weight-management drug that is growing sales by leaps and bounds.

Here's what investors should know before adding either one to their portfolios. Viking Therapeutics shares rocketed to an all-time high last February after the company announced positive clinical ...

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics VKTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...